Paraoxonase-1 is not associated with coronary artery calcification in type 2 diabetes: Results from the PREDICT study

Disease Markers

Volumn 33, Issue 2, 2012, Pages 101-112

  MacKness, Bharti ^a   Marsillach, Judit ^b   Elkeles, Robert S ^c   Godsland, Ian F ^c   Feher, Michael D ^d   Rubens, Michael B ^e   Flather, Marcus D ^f   Humphries, Steve E ^g   Cooper, Jackie ^g   MacKness, Mike ^a  

^a Calle de l'Argelagar   (Spain)

^b UNIVERSITY OF WASHINGTON   (United States)

^c ST MARY S HOSPITAL   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

coronary calcification; insulin resistance; Paraoxonase 1; Type 2 diabetes

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 192; ARYLDIALKYLPHOSPHATASE 55; CREATININE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN; STATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; ASIA; BLOOD LEVEL; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; ETHNICITY; FEMALE; GENOTYPE; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84864454310     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2012/953768     Document Type: Article

References (46)

1. Pyorala K, Laakso M. Macrovascular disease in diabetes, in: Mann J, Pyorala K, Teuscher A. (ed.), Diabetes in Epidemiological Perspective. Churchill Livingstone, 1983, 183-247.
2. Ardehali R, Nasir K, Kolandaivelu A, Budoff M, Blumenthal RS. Screening patients for subclinical atherosclerosis with non-contrast cardiacCT. Atherosclerosis 192 (2007), 235-242.
3. Arad Y, Goodman KJ, RothM, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C- reactive protein and atherosclerotic cardiovascular disease events: The St Francis Heart Study. JAm Coll Cardiol 46 (2005), 158-165.
4. Elkeles RS, Godsland IF, Feher MD, Rubens MB, Roughton M, Nugara F, Humphries SE, RichmondW, FlatherMD. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: The PREDICT study. Eur Heart J 29 (2008), 2244-2251.
5. Primo-Parma, SL, Sorenson, RC, Teiber, J, La Du, BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33 (1996), 498-509.
6. Rodriguez-Sanabria F, Rull A, Beltran-Debon R, Aragones G, Camps J, Mackness B, Mackness M, Joven J. Tissue distribution and expression of paraoxonases and chemokines in the mouse: The ubiquitous and joint localisation suggest a systemic and coordinated role. J Mol Histol 41 (2010), 379-386.
7. Mackness, B, Durrington, PN, Mackness, MI. The paraoxonase gene family and coronary heart disease. Curr. Opinion. Lipidol 13 (2002), 357-362.
8. Reddy ST, Devarajan A, Bourquard N, Shih D, Fogelman AM. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis? Curr Opin Lipidol 19 (2008), 405-408.
9. Liu, Y,Mackness, B, Mackness, M. Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress. Free Rad Biol Med 45 (2008), 743-748.
10. Rozenberg, O, Shih, DM, Aviram, M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: Studies in PON1 transfected cells and in PON1 transgenic mice. Atheros- clerosis 181 (2005), 9-18.
11. Mackness, B, Quarck, R, Verreth, W, Mackness, M, Holvoet, P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 26 (2006), 1545-1550.
12. Guns, P-J, Van Assche, T, Verreth, W, Fransen, P, Mackness, B, Mackness, M, Holvoet, P, Bull, H. Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with preexisting atherosclerosis. Br J Pharmacol 153 (2008), 508-516.
13. Ng CJ, Hama SY, Bourquard N, Navab M, Reddy ST. Adenovirus mediated expression of human paraoxonase 2 pro tects against Development of atherosclerosis in apolipoprotein E-deficient mice. Mol Genet Metab 89 (2006), 368-373.
14. Ng CJ, Bourquard N, Hama SY, Shih D, Grijalva VR, Navab M, Fogelman AM, Reddy ST. Adenovirus mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27 (2007), 1368-1374.
15. Mackness, B, Hunt, R, Durrington, PN, Mackness, MI. Increased immunolocalisation of paraoxonase, clusterin and apolipoprotein AI in the human artery wall with progression of atherosclerosis. Arterioscler Thromb Vasc Biol 17 (1997), 1233-1238.
16. Marsillach J, Camps J, Beltran-Debon R, Rull A, Aragones G, Maestre-Martinez C, Sabench F, Hernandez M, Del Castillo D, Joven J, Mackness M, Mackness B. Immunohistochemical analysis of paraoxonases 1 and 3 in human atheromatous plaques. Eur J Clin Invest 41 (2011), 308-314.
17. Mackness, B, Mackness, MI, Arrol, S, Turkie, W, Julier, K, Abuashia, B, Miller, JE, Boulton, AJM, Durrington, PN. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin Dependent diabetes mellitus. Atherosclerosis 139 (1998), 341-349.
18. Mastorikou, M, Mackness, M, Mackness, B. Defective metabolism of oxidised-phospholipid by high-density lipoprotein from people with type 2 diabetes. Diabetes 55 (2006). 3099-3103.
19. Elkeles RS, Flather M, Feher MD, Godsland I, Richmond W, Humphries SE, Rubens MB, Underwood SR. Prospective evaluation of diabetic ischaemic heart disease by computed tomography: The PREDICT study. Br J Diabetes Vasc Dis 2 (2002), 69-72.
20. Wild S, Mckeigue P. Cross sectional analysis of mortality by country of birth in England andWales 1970-92. Br Med J 314 (1997), 705-710.
21. Agaston AS, Janowitz WR, Hilner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultafast computed tomography. J Am Coll Cardiol 15 (1990), 827-832.
22. Elkeles RS, Feher MD, Flather MD, Godsland IF, Nugara F, Richmond W, Rubens MD,Wang D. The association of calcium score and conventional risk factors in type 2 diabetic subjects asymptomatic for coronary heart disease (The PREDICT study). Diab Med 21 (2004), 1129-1134.
23. Godsland IF, Elkeles RS, Feher MD, Nugara F, Rubens MB, Richmond W, Khan M, Donovan J, Anyaoku V, Flather MD. Coronary calcification, homocysteine, C-reactive protein and the metabolic syndrome in type 2 diabetes: The PREDICT study. Diab Med 23 (2006), 1192-2000.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Lnsulin resistance and â-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412-419.
25. Alberti KG, Zimmet P, Shaw J, IDF ETFCG. The metabolic syndrome - a new worldwide Definition. Lancet 366 (2005), 1059-1062.
26. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness, M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 (2003), 2775-2779.
27. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan M-L, Allayee H, Lusis AJ, Hazen SL. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299 (2008), 1265-1276.
28. van Himbergen TM, van Der Schouw YT, Voorbij HAM, van Tits LJH, Stalenhoef AFH, Peeters PHM, Roest M. Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis 198 (2008), 408-414.
29. Ikeda Y, Inoue M, Suehiro T, Arii K, Kumon Y, Hashimoto K. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol 46 (2009), 239-242.
30. Troughton JA, Woodside JV, Yarnell JWG, Arveiler D, Amouyel P, Ferrieres J, Ducimetiere P, Patterson CC, Luc G. Paraoxonase activity and coronary heart disease in healthy middle-aged males: The PRIME study. Atherosclerosis 197 (2008), 556-563.
31. Birjmohun RS, Vergeer M, Stroes ES, Sandhu MS, Ricketts SL, TanckMW,Wareham NJ, Jukema JW, Kastelein JJ, Khaw KT, Boekholdt SM. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC- Norfolk prospective population study. PLoS One 4 (2009), e6809.
32. Ikeda Y, Suehiro T, Itahara T, Inui Y, Chikazawa H, Inoue M, Arii K, Hashimoto K. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol 67 (2007), 358-365.
33. Mackness B, Davies GK, TurkieW, Lee E,Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI. Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype? Arterioscler. Thromb Vasc Biol 21 (2001), 1451-1457.
34. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: Meta-analysis of 43 studies. Lancet 363 (2004), 689-95.
35. Thyagarajan B, Jacobs DR jr, Carr JJ, Alozie O, Steffes MW, Kailash P, Hayes JH, Gross MD. Factors associated with paraoxonase genotypes and activity in diverse, young, healthy population: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin Chem 54 (2008), 738-46.
36. Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Carr JJ, Freedman BI, Herrington D, Bowden DW. Association of genes of lipid metabolism with measures of subclinical cardiovascular disease in the Diabetes Heart Study. J Med Genet 42 (2005), 720-4.
37. Rozenberg O, Shiner M, Aviram M, Hayek T. Paraoxonase 1 (PON1) attenuates diabetes Development in mice through its antioxidative properties. Free Rad Biol Med 44 (2008), 1951-1959.
38. Koren-Gluzer M, Aviram M, Meilin E, Hayek T. The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes Development and stimulates â-cell insulin release. Atherosclerosis (2011) doi: 10.1016/j.atherosclerosis.2011. 07.119.
39. Bourquard N, Ng CJ, Reddy ST. Impaired hepatic insulin signalling in PON2-deficient mice: A novel role for the PON2/apoE axis on the macrophage inflammatory response. Biochem J 436 (2011), 91-100.
40. Kordonouri O, James, RW, Bennetts JB, Chan A, Kao YL, Danne T, SilinkM,Donaghue K. Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 50 (2001), 657-660.
41. Ikeda Y, Suehiro T, Arii K, Kumon Y, Hashimoto K. High glucosa induces transactivation of the human paraoxonase 1 gene in hepatocytes. Metabolism 57 (2008), 1725-1732.
42. Aviram M, Rosenblat M, Scott B, Drogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B. Human serum paraoxonase (PON1) is inactivated by oxidised low Density lipoprotein and preserved by antioxidants. Free Rad. Biol. Med. 26 (1999), 892-904.
43. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 107 (2010), 1058-1070.
44. Van Der Gaag MS, van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, Hendriks HF. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet controlled, randomised intervention study in middle-aged men. Atherosclerosis 147 (1999), 405-410.
45. Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol 66 (2008), 366-374.
46. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: A role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 23 (2003), 2083-2089.